Acceptability and Persistence of the Use of a Patient-centred E-health Tool for Lupus Patients Followed in a Specialised Centre in France

Overview

Systemic lupus erythematosus (SLE) is a complex disease whose evaluation in daily practice and clinical research requires consideration of several aspects, in particular disease activity and quality of life. Health systems are increasingly using Patient Reported Outcome measures (PRO) data to measure different dimensions of the disease and its experience. In addition, there is a growing number of "e-health" tools for patients. Indeed, the collection of health-related data via an electronic system makes it possible to modernise and facilitate communication between patients and doctors within the framework of medical follow-up and therapeutic education. Nevertheless, very few studies measure the acceptability and effective long-term use of such tools, particularly in the context of SLE. The Sanoïa patient platform is a digital tool already used in therapeutic areas similar to SLE (discoid lupus erythematosus and rheumatoid arthritis), offering a guarantee of safety and a reduced individual cost. The availability of this health-related quality of life data collection tool via a site and a mobile application adapted to patients with SLE should: – Facilitate the collection by patients of their quality of life as part of their routine follow-up (patient access) – Limit the impact of patients' clinical profiles on the frequency of the collection of quality of life data – Enable internal medicine specialists to systematically use their patients' quality of life data during consultation (physician access). This study therefore proposes to evaluate this digital platform within the framework of SLE by measuring the distribution of access by physicians according to the data reported by patients and according to the characteristics of the facilities where the subjects were recruited for the study. These data will allow us to evaluate the influence of factors extrinsic to patients on the adoption of the tool. This area has been very poorly evaluated in the few studies that have focused on the adoption of such tools.

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: December 5, 2022

Interventions

  • Other: use of e-Health service
    • use of the e-Health e-Lupus account (at least) once a month and encouraged to advise his doctor to consult the entered data before the following consultation

Clinical Trial Outcome Measures

Primary Measures

  • utilization rate of online patient account
    • Time Frame: Through study completion, an average of 24 months
    • rate of use of the patient account at least twice, at least 1 month apart, over a 12-month period

Participating in This Clinical Trial

Inclusion Criteria

  • Adult > 18 years old – Having given oral consent for participation – Confirmed systemic lupus diagnosis (ACR criteria) – Regular follow-up in the centre for more than 12 months – With Internet access at home – Affiliated with national health insurance system or other system Exclusion Criteria:

  • Persons subject to a legal protection measure (curatorship, guardianship) – Persons subject to limited judicial protection – Adults who are incapable or unable to express their consent – Patients who cannot read French – Patients whose cognitive status does not allow them to track their health data on a digital platform – Patients to be followed up in another centre within 12 months

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Centre Hospitalier Universitaire Dijon
  • Provider of Information About this Clinical Study
    • Sponsor

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.